Free tool
FAERS Monitor: Chorionic Gonadotropin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 017016 or its brand name (Chorionic Gonadotropin, Gonadotropin, Chorionic). Reports on generic versions are filed under their own applications.
Reports
1,179
Serious
748
63% of reports
Hospitalization
412
Death reported
30
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- ovarian hyperstimulation syndrome244
- drug ineffective94
- nausea74
- off label use68
- abdominal distension60
- headache60
- dyspnoea51
- ascites50
- vomiting44
- abortion spontaneous41
- pain40
- fatigue39
- drug exposure during pregnancy38
- product use in unapproved indication37
- abdominal pain36
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 9 |
| 2005 | 27 |
| 2006 | 28 |
| 2007 | 45 |
| 2008 | 20 |
| 2009 | 29 |
| 2010 | 27 |
| 2011 | 53 |
| 2012 | 81 |
| 2013 | 22 |
| 2014 | 18 |
| 2015 | 9 |
| 2016 | 44 |
| 2017 | 28 |
| 2018 | 51 |
| 2019 | 88 |
| 2020 | 56 |
| 2021 | 74 |
| 2022 | 121 |
| 2023 | 114 |
| 2024 | 72 |
| 2025 | 80 |
| 2026 | 83 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,980 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ovarian hyperstimulation syndromeSignal | 244 | 2085.7 | 1850.4 | 453,433 |
| ascitesSignal | 50 | 30.4 | 23.2 | 1,392 |
| drug exposure during pregnancySignal | 38 | 20.0 | 14.6 | 666 |
| abortion spontaneousSignal | 41 | 18.3 | 13.5 | 653 |
| abdominal distensionSignal | 60 | 10.3 | 8.0 | 494 |
| abdominal painSignal | 36 | 2.8 | 2.0 | 39 |
| product use in unapproved indicationSignal | 37 | 2.7 | 1.9 | 37 |
| headache | 60 | 1.7 | 1.3 | 17 |
| vomiting | 44 | 1.7 | 1.2 | 11 |
| nausea | 74 | 1.7 | 1.3 | 20 |
| dyspnoea | 51 | 1.6 | 1.2 | 11 |
| off label use | 68 | 1.4 | 1.1 | 7 |
| drug ineffective | 94 | 1.3 | 1.0 | 6 |
| pain | 40 | 1.2 | 0.9 | 1 |
| fatigue | 39 | 0.9 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.